Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo in relapsed/refractory Hodgkin lymphoma (ANIMATE)
NCT03337919Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Dec 2018
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by University College London. Started Dec 2018; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03337919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337919.